Colorectal cancer (CRC) treatment is rapidly evolving from traditional chemotherapy to personalized, molecularly guided therapies. Precision medicine allows clinicians to analyze tumor genetics and target mutations in genes like RAS, BRAF, and HER2, providing new options for previously hard-to-treat subtypes. Immunotherapy has been particularly impactful for the 5–15% of CRC tumors that are microsatellite instability-high (MSI-H), with drugs like pembrolizumab stimulating the immune system to attack cancer and, in some rectal cancer cases, even achieving complete responses that may avoid surgery.
Additional innovations include antibody-drug conjugates (ADCs), which deliver chemotherapy directly to tumor cells, and oncolytic viruses and cancer vaccines that train the immune system to recognize and destroy cancer. Liquid biopsies are also transforming care by allowing early detection of recurrence and real-time monitoring of treatment effectiveness through simple blood tests. Together, these approaches are ushering in a more precise, effective, and individualized era of CRC therapy.